Reducing TBK1/IKKε activity decreased active YAP/TAZ and attenuated PAH‐associated remodeling phenotypes for a sustained period compared with treprostinil, a currently approved PAH treatment, which was short‐acting. This evidence concerns the gene TBK1 and pulmonary arterial hypertension.